MktsMarkets

Capricor Therapeutics, Inc.
NASDAQ: CAPRKey statistics
CAPR News
Stories mentioning CAPR from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 11,130 | 2,262 | 3,971 | |||||
| Cost of Goods Sold | ||||||||
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Operating Expenses | ||||||||
| Research & Development | 27,377 | 23,133 | 20,359 | 22,047 | 18,916 | 14,555 | 11,808 | 12,505 |
| Sales General & Admin | ||||||||
| Total Operating Expenses | 36,773 | 29,156 | 26,284 | 27,719 | 24,983 | 18,826 | 15,272 | 15,563 |
| Operating Income (Loss) | (36,773) | (29,156) | (26,284) | (27,719) | (24,983) | (7,696) | (13,010) | (11,591) |
| Interest Income | ||||||||
| Interest Expense | ||||||||
| Other Expense | ||||||||
| Pretax Income | (33,941) | (24,392) | ||||||
| Tax Provision | 0.00 | 0.00 | ||||||
| Net Income (Loss) | (33,941) | (30,170) | (24,571) | (25,911) | (24,392) | (7,116) | (12,557) | (11,000) |
| Earnings Per Share (Basic) | (0.59) | (0.65) | (0.54) | (0.57) | (0.53) | (0.20) | (0.38) | (0.35) |
| Earnings Per Share (Diluted) | (0.59) | (0.65) | (0.54) | (0.57) | (0.53) | (0.20) | (0.38) | (0.35) |
| Weighted Average Shares Outstanding (Basic) | 57,434 | 46,478 | 45,716 | 45,709 | 45,637 | 35,219 | 33,090 | 31,842 |
| Weighted Average Shares Outstanding (Diluted) | 57,434 | 46,478 | 45,716 | 45,709 | 45,637 | 35,219 | 33,090 | 31,842 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About CAPR
Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a stock listed on the Nasdaq Stock Market under the ticker symbol CAPR. It last traded at $7.59 (Nov 20, 2026, 4:00 PM ET), up 0.8% on the day. That gives Capricor Therapeutics a market capitalisation of $460.5M.
Over the past 52 weeks CAPR has traded between $2.96 and $40.37.
For the quarter ended Mar 31, 2026 it reported a net loss of $33.9M.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Mar 31, 2026 | — | -$33.9M |
| Dec 31, 2025 | — | -$30.2M |
| Sep 30, 2025 | — | -$24.6M |
| Jun 30, 2025 | — | -$25.9M |
From Capricor Therapeutics’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…